Topical Yunnan Baiyao administration as an adjunctive therapy for bleeding complications in adolescents with advanced cancer

• Published in: Supportive care in cancer 2012-12, Vol.20 (12), p.3379-3383
• Main Authors: Ladas, E. J., Karlik, J. B., Rooney, D., Taromina, K., Ndao, D. H., Granowetter, L., Kelly, K. M.
• Format: Article
• Language: English
• Subjects: Administration, Topical; Adolescent; Cancer; Case Study; Complications and side effects; Drugs, Chinese Herbal - therapeutic use; Epistaxis - drug therapy; Epistaxis - etiology; Female; Hemorrhage; Hemorrhage - drug therapy; Hemorrhage - etiology; Hemostatics - therapeutic use; Herbal medicine; Humans; Liver cancer; Male; Medicine; Medicine & Public Health; Neoplasms - complications; Nursing; Nursing Research; Oncology; Pain Medicine; Palliative care; Palliative Care - methods; Powders; Rehabilitation Medicine; Retrospective Studies; Teenagers; Thrombin; Youth
• ISSN: 0941-4355; 1433-7339
• DOI: 10.1007/s00520-012-1598-1

Purpose Yunnan Baiyao (White Medicine from Yunnan, YNB) is a Chinese herbal medicinal powder used to stop bleeding and improve circulation in traumatic injuries. We describe the use of YNB in adolescents with cancer as an adjunct to uncontrolled bleeding in the palliative care setting. Methods Through a retrospective chart review of all patients receiving integrative medicine consultations at the Integrative Therapies Program at Columbia University from January 1, 2007 to January 31, 2012, we describe the outcome of patients treated with YNB for management of uncontrolled bleeding. Results Four patients were identified who received topical YNB for uncontrolled bleeding; patients included two males and two females with diagnoses of solid tumors ( n  = 3) and Burkitt’s lymphoma ( n  = 1). Mean age was 15.5 years (range 15–17). Fifty percent had life-threatening bleeding from the tumor site and 50 % experienced uncontrollable epistaxis. All patients received preceding therapy with packed red blood cells and platelet transfusions, topical thrombin, and oral aminocaproic acid. Two patients used YNB in the inpatient setting, and all four patients used YNB as outpatients. In all patients, bleeding control improved with the addition of YNB to conventional hemostatic interventions. Two patients using YNB in their home reported control of bleeding episodes. There were no adverse events reported. Conclusions YNB may be an efficacious agent for uncontrolled bleeding in conjunction with conventional hemostatic agents in adolescents with advanced cancer. It is well accepted by patients. YNB may be especially valuable in the outpatient setting to prevent the recurrence of hemorrhage.